Palvella Therapeutics Wins 2026 PACT Healthcare & Life Sciences Company of the Year Award
WAYNE, Pa., May 21, 2026 Palvella Therapeutics announced that it has been named Healthcare & Life Sciences Company of...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
WAYNE, Pa., May 21, 2026 Palvella Therapeutics announced that it has been named Healthcare & Life Sciences Company of...
WAYNE, Pa., May 15, 2026 Palvella Therapeutics announced new positive Phase 2 TOIVA trial data for QTORINâ„¢ rapamycin in...
WAYNE, Pa., Feb. 24, 2026 — Palvella Therapeutics announced positive topline results from its Phase 3 SELVA clinical study...
